![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1
|
|
|
CROI February 19-22, 2023; Virtual and Seattle, WA
Franco Felizarta1, Ronald D’Amico2, Kehui Wang3, Herta Crauwels4, Mar Masia5, Miguel Garcia Deltoro6, Olaf Degen7, Jonathan Angel8, Chiu-Bin Hsiao9, Vasiliki Chounta2, Kelong Han3, Conn Harrington2, Kelly Rimler3, William R. Spreen2, Susan L. Ford10
1Private Practice, Bakersfield, California, United States; 2ViiV Healthcare, Durham, NC, United States; 3GSK, Collegeville, PA, United States; 4Janssen Research & Development, Beerse, Belgium; 5Hospital General Universitario de Elche, Alicante, Spain; 6Consorcio Hospital General Universitario de Valencia, Valencia, Spain; 7University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 8University of Ottawa, Ottawa, ON, Canada; 9Medicine Institute, School of Medicine, Infectious Diseases, Drexel University, Positive Health Clinic, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA, United States; 10GSK, Durham, NC, United States
![0223231](../images/022423/022423-8/0223231.gif)
![0223232](../images/022423/022423-8/0223232.gif)
![0223233](../images/022423/022423-8/0223233.gif)
![0223234](../images/022423/022423-8/0223234.gif)
![0223235](../images/022423/022423-8/0223235.gif)
![0223236](../images/022423/022423-8/0223236.gif)
![0223237](../images/022423/022423-8/0223237.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|